Cepheid  

(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for CPHD
55.71
-0.62 (-1.10%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 55.29 - 56.85
52 week 36.94 - 63.69
Open 56.04
Vol / Avg. 0.00/799,125.00
Mkt cap 4.04B
P/E     -
Div/yield     -
EPS -0.66
Shares 71.53M
Beta 0.77
Inst. own 100%
Oct 14, 2015
Q3 2015 Cepheid Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 27, 2015
Cepheid Analyst Event
Jul 23, 2015
Q2 2015 Cepheid Earnings Call - Webcast
Jul 23, 2015
Q2 2015 Cepheid Earnings Release
Jun 24, 2015
Cepheid at JMP Securities Life Sciences Conference
Jun 10, 2015
Cepheid at Goldman Sachs Healthcare Conference
Jun 9, 2015
Cepheid at William Blair Annual Growth Stock Conference
Jun 3, 2015
Cepheid at Jefferies Global Healthcare Conference
May 13, 2015
Cepheid at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -12.63% -10.67%
Operating margin -8.11% -7.25%
EBITD margin - 3.70%
Return on average assets -8.19% -8.44%
Return on average equity -17.87% -15.68%
Employees 1,400 -
CDP Score - -

Address

904 Caribbean Drive
SUNNYVALE, CA 94089
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ilan Daskal Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Chief Operating Officer, Principal Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
David H. Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Corporate Development, General Counsel
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Farrell Executive Vice President - International Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Michael Fitzgerald Executive Vice President, Global Human Resources
Age: 55
Bio & Compensation  - Reuters
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 63
Bio & Compensation  - Reuters
Daniel E. Madden Vice President, Corporate Controller
Age: 47
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 69
Bio & Compensation  - Reuters